Crinetics Pharmaceuticals, Inc.
CRNX Real Time Price USDRecent trades of CRNX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Josh Gottheimer House / D | Purchase $1,001 - $15,000 | Sep. 25, 2024 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CRNX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof Nov. 05, 2024
-
Patent Title: Formulations of a somatostatin modulator Apr. 16, 2024
-
Patent Title: Somatostatin modulators and uses thereof Dec. 05, 2023
-
Patent Title: Crystalline forms of a somatostatin modulator Oct. 03, 2023
-
Patent Title: Somatostatin modulators and uses thereof Mar. 21, 2023
-
Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Jan. 31, 2023
-
Patent Title: Nonpeptide somatostatin type 5 receptor agonists and uses thereof Oct. 25, 2022
-
Patent Title: Somatostatin modulators and uses thereof Aug. 16, 2022
-
Patent Title: Formulations of a somatostatin modulator Mar. 08, 2022
-
Patent Title: Somatostatin modulators and uses thereof Nov. 30, 2021
-
Patent Title: Somatostatin modulators and uses thereof Jul. 27, 2021
-
Patent Title: Somatostatin modulators and uses thereof Jun. 08, 2021
-
Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Apr. 20, 2021
-
Patent Title: Process of making somatostatin modulators Jan. 12, 2021
-
Patent Title: Somatostatin modulators and uses thereof Dec. 29, 2020
-
Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Sep. 08, 2020
-
Patent Title: Somatostatin modulators and uses thereof Jun. 30, 2020
-
Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Feb. 18, 2020
-
Patent Title: Process of making somatostatin modulators Nov. 05, 2019
-
Patent Title: Somatostatin modulators and uses thereof Jul. 16, 2019
-
Patent Title: Somatostatin modulators and uses thereof May. 01, 2018
-
Patent Title: Somatostatin modulators and uses thereof Feb. 27, 2018
-
Patent Title: Somatostatin modulators and uses thereof Feb. 20, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of CRNX in WallStreetBets Daily Discussion
Recent insights relating to CRNX
Recent picks made for CRNX stock on CNBC
ETFs with the largest estimated holdings in CRNX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CRNX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.